J Greenhalgh1, H Ford, A F Long, K Hurst. 1. Health Care Practice R&D Unit, University of Salford, Allerton Building, Frederick Road, Salford M6 4WT, UK.
Abstract
OBJECTIVES: This study aimed to develop further a diary originally devised to measure the impact of multiple sclerosis (MS) as part of a cost utility study of beta interferon, and to evaluate its reliability, validity, and responsiveness in an outpatient sample of people with MS. METHODS: The original diary was further developed using qualitative and quantitative methods to ensure that it addressed the views of people with MS. The psychometric properties of the MS Symptom and Impact Diary (MSSID) were evaluated in a sample of 77 people who completed the MSSID daily for 12 weeks. Internal and test-retest reliability, discriminant and convergent validity, and responsiveness were assessed using traditional psychometric methods. RESULTS: The MSSID formed three, internally consistent scales that measured mobility, fatigue, and the overall impact of MS. The test-retest reliability of the mobility scale was adequate for individual comparisons (ICC>0.90) and the fatigue and overall impact scales were adequate for group comparisons (ICC>0.70). The MSSID was able to distinguish between clinical groups depending on clinical course, indoor ambulation status, and relapse status. It demonstrated associations with other single point instruments in the expected direction. Compared with single point instruments, its responsiveness was similar or better, especially in detecting short term improvements in functioning. CONCLUSIONS: The MSSID may provide a useful complement to currently available instruments to measure the outcomes of MS within clinical trials. Further research is needed to explore its feasibility in the context of a randomised controlled trial and its utility for clinicians.
OBJECTIVES: This study aimed to develop further a diary originally devised to measure the impact of multiple sclerosis (MS) as part of a cost utility study of beta interferon, and to evaluate its reliability, validity, and responsiveness in an outpatient sample of people with MS. METHODS: The original diary was further developed using qualitative and quantitative methods to ensure that it addressed the views of people with MS. The psychometric properties of the MS Symptom and Impact Diary (MSSID) were evaluated in a sample of 77 people who completed the MSSID daily for 12 weeks. Internal and test-retest reliability, discriminant and convergent validity, and responsiveness were assessed using traditional psychometric methods. RESULTS: The MSSID formed three, internally consistent scales that measured mobility, fatigue, and the overall impact of MS. The test-retest reliability of the mobility scale was adequate for individual comparisons (ICC>0.90) and the fatigue and overall impact scales were adequate for group comparisons (ICC>0.70). The MSSID was able to distinguish between clinical groups depending on clinical course, indoor ambulation status, and relapse status. It demonstrated associations with other single point instruments in the expected direction. Compared with single point instruments, its responsiveness was similar or better, especially in detecting short term improvements in functioning. CONCLUSIONS: The MSSID may provide a useful complement to currently available instruments to measure the outcomes of MS within clinical trials. Further research is needed to explore its feasibility in the context of a randomised controlled trial and its utility for clinicians.
Authors: Peter J Jongen; Dirk Lehnick; Evert Sanders; Pierette Seeldrayers; Sten Fredrikson; Magnus Andersson; Joachim Speck Journal: Health Qual Life Outcomes Date: 2010-11-15 Impact factor: 3.186
Authors: Vivian W Sung; Melissa A Clark; Eric R Sokol; Charles R Rardin; Deborah L Myers Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2006-11-18
Authors: Chloé Sieber; Deborah Chiavi; Christina Haag; Marco Kaufmann; Andrea B Horn; Holger Dressel; Chiara Zecca; Pasquale Calabrese; Caroline Pot; Christian Philipp Kamm; Viktor von Wyl Journal: JMIR Mhealth Uhealth Date: 2022-10-05 Impact factor: 4.947
Authors: Celia Oreja-Guevara; Stanca Potra; Birgit Bauer; Diego Centonze; Maria-Paz Giambastiani; Gavin Giovannoni; Jürg Kesselring; Dawn Langdon; Sarah A Morrow; Jocelyne Nouvet-Gire; Maija Pontaga; Peter Rieckmann; Sven Schippling; Nektaria Alexandri; Jane Shanahan; Heidi Thompson; Pieter Van Galen; Patrick Vermersch; David Yeandle Journal: Adv Ther Date: 2019-09-05 Impact factor: 3.845
Authors: Peter Joseph Jongen; Marco Heerings; Wim A Lemmens; Rogier Donders; Anneke van der Zande; Esther van Noort; Anton Kool Journal: BMC Neurol Date: 2015-08-04 Impact factor: 2.474
Authors: Karine Baumstarck; Helmut Butzkueven; Oscar Fernández; Peter Flachenecker; Sergio Stecchi; Egemen Idiman; Jean Pelletier; Mohamed Boucekine; Pascal Auquier Journal: Health Qual Life Outcomes Date: 2013-07-29 Impact factor: 3.186